• Oct 5, 2026

  $37.54+0.59%

• Oct 2, 2026

  $37.32-0.21%

  Novo Nordisk shares closed down 0.21%. Seeking Alpha reported that the FDA extended its review of the company's denecimig for hemophilia A, as facility remediation prolonged the BLA review [1]. The Motley Fool reported that the company struck two deals worth nearly $4 billion [2].

  • 1Seeking Alpha
  • 2The Motley Fool

• Oct 1, 2026

  $37.40-1.35%

  Seeking Alpha reported that Regeneron's trevogrumab, combined with Novo's semaglutide, cut muscle loss in obesity patients in new trial data [2]. Seeking Alpha also reported a late-stage study of a Lilly diabetes drug [1]. Neither item says why Novo shares fell 1.35%.

  • 1Seeking Alpha
  • 2Seeking Alpha

• Sep 30, 2026

  $37.91-1.04%

• Sep 29, 2026

  $38.31-1.03%

  Seeking Alpha reported that Novo Nordisk licensed Hengrui's obesity drug HRS-1596 in a deal worth up to $2.6B [1]. Novo said Ozempic 2 mg cut major cardiovascular events compared with Lilly's Mounjaro in a real-world claims analysis [2], while Lilly said Zepbound at higher doses topped Novo's Wegovy HD [3] and that Foundayo beat oral semaglutide on weight loss [4].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Seeking Alpha
  • 4Seeking Alpha

• Sep 28, 2026

  $38.71-0.23%

• Sep 25, 2026

  $38.80+0.47%

  Novo Nordisk signed a deal worth up to $1.3B with Nanexa for its PharmaShell drug-delivery technology for obesity and diabetes peptides [2]. Separately, Viatris filed suit seeking court approval to market a generic version of Wegovy, challenging Novo Nordisk's patent [1].

  • 1Seeking Alpha
  • 2Seeking Alpha

Closing prices for NVO. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.